Autolus Therapeutics plc American Depositary Share 2026 Q2 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Autolus Therapeutics reported second quarter 2026 net product revenue of $45.7 million, a significant increase from $26 million in the first quarter and $20.9 million in the second quarter of 2025.
- For the first half of 2026, net revenue reached $71.9 million, nearly matching the full year revenue from the first year of launch in 2025.
- The company expanded its commercial presence to over 80 centers in the US by mid-year and continued adding centers in the second half of 2026, with around 20 authorized treatment centers in the UK.
- Gross margin improved to 55% in Q2 2026, up from 6% in Q1 and negative margins in 2025 quarters, driven by increased production volumes and operational efficiencies.
- Operating expenses included R&D of $27.9 million, flat year-over-year, and SG&A of $41.2 million, up from $30.3 million in Q2 2025, partly due to one-time termination expenses.
- Loss from operations was $43.8 million in Q2 2026 compared to $61.2 million in Q2 2025, and net loss was $39.1 million versus $47.9 million in the prior year period.
- The company secured a $250 million senior credit facility with Perceptive Advisors, with $75 million drawn at closing and $25 million available within six months, plus up to $150 million contingent on revenue milestones.
- Cash, cash equivalents, and marketable securities totaled $201.6 million at June 30, 2026, excluding the credit facility drawdown, providing runway into Q2 2028.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first five paragraphs, organized by speaker.
Good day, and thank you for standing by. Welcome to the Autolus Therapeutics second quarter 2026 financial results conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star one one on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star one one again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Executive Director of Investor Relations, Amanda Cray. Please go ahead. Thank you, DeeDee.
Good morning or good afternoon, everyone, and thank you for joining us on today's call. With me, our Chief Executive Officer, Dr. Christian Itin, and Chief Financial Officer, Rob Dolski. I'd like to remind you that during today's call, we will make statements related to our business that are forward-looking under federal securities laws and the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These may include, but are not limited to, statements regarding the status of ongoing commercial launch of AUCATZYL in the U.S. and U.K., Autolus manufacturing, sales, and marketing plans for AUCATZYL, the market potential for AUCATZYL, and the status of clinical trials, development and/or regulatory timelines and market opportunities for obe-cel and our other product candidates.
These statements are subject to a variety of risks and uncertainties that could cause actual results to differ materially from expectations and reflect our views only as of today. We assume no obligation to update any such forward-looking statements. For a discussion of the material risks and uncertainties that could affect our actual results, please refer to the risks identified in today's press release and in our SEC filings, both available on the investors section of our website. On slide 3, you'll see the agenda for today's call. As usual, Christian will provide an overview of our operational highlights. Rob will then discuss the financial results, and Christian will conclude with upcoming milestones and closing remarks. We'll then take questions. With that, I'm happy to turn it over to Christian.
Thanks, Amanda, and welcome everybody to our second quarter call. We're moving to slide number 4. We had a very positive second quarter with strong AUCATZYL sales growth in our second year of launch now. When we look at the AUCATZYL revenue in the second quarter, we're at GBP 45.7 million, which is a substantial increase over the GBP 26 million that we had in the first quarter. For the first half of the year, we reached GBP 71.9 million, which is close to the full year number that we had for our first year of launch last year. We see that the positive experience that the physicians are having with the product in the centers that we're active in, which is also reflected in the data that was collected by the ROCCA Consortium and the real world database that was presented at the Tandem meeting.
It builds a very strong foundation for the adoption of the product. I think the continued positive momentum that we're seeing in the market. We also obviously have continued to grow our presence, from a center perspective. We had indicated at the beginning of the year that we would reach in the range of 80 centers for the full year. We're now at the mid-year point, and we're above 80 centers already, and we continue to add centers in the second half of the year as well. When we look to the U.K., we started the launch at the beginning of the year. We do see strong initial adoption and we obviously continue to also add treatment centers as we go through the remainder of the year. With that, we're going to move to slide number 5.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
13 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring